Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol (PEG) + simethicone is a combination therapy used for bowel cleansing prior to gastrointestinal procedures such as colonoscopy and capsule endoscopy. Polyethylene glycol acts as an osmotic laxative, inducing a watery diarrhea that clears the colon of fecal matter. Simethicone is a non-absorbable surfactant that acts as an antifoaming agent by reducing the surface tension of gas bubbles in the digestive tract. This reduction in bubbles improves mucosal visualization, particularly in the right colon, and may reduce patient symptoms like bloating and abdominal discomfort. Clinical trials have demonstrated that the addition of simethicone to standard PEG regimens (ranging from 2L to 4L) significantly improves bubble scores and mucosal visibility without compromising the safety or tolerability of the preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + simethicone.